(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 15.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Harmony Biosciences Holdings's revenue in 2024 is $617,511,000.On average, 3 Wall Street analysts forecast HRMY's revenue for 2024 to be $40,580,624,278, with the lowest HRMY revenue forecast at $40,007,026,481, and the highest HRMY revenue forecast at $41,122,986,550. On average, 2 Wall Street analysts forecast HRMY's revenue for 2025 to be $47,935,170,277, with the lowest HRMY revenue forecast at $47,000,944,164, and the highest HRMY revenue forecast at $48,869,396,391.
In 2026, HRMY is forecast to generate $53,886,957,310 in revenue, with the lowest revenue forecast at $51,760,102,115 and the highest revenue forecast at $56,013,812,504.